酸酶CTDSPL2促进了骨髓瘤中扩散,入侵,转移和对regorafenib的抗性
Guannan Bai1, Shaobo Zhao1, Manli Zhao2
1Department of Orthopedics, Children's Hospital, Zhejiang University School of Medicine, National Children's Regional Medical Center, National Clinical Research Center for Child Health, 3333 Binsheng Road, Hangzhou, Zhejiang Province 310052, China.
研究人员确定CTDSPL2是驱动骨髓瘤恶性病变和对Regorafenib治疗的抗性的一个关键基因. 向CTDSPL2显示了通过抑制瘤生长和扩散来治疗晚期骨髓瘤的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学是一种遗传学.
背景情况:
- 骨肉瘤是儿童和青少年患有骨癌的流行病,转移性或复发性病例的预后不佳.
- 雷戈拉费尼布是一种用于高级骨髓瘤治疗的多酶抑制剂,但抵抗机制尚不清楚.
研究的目的:
- 为了阐明骨髓瘤中对regorafenib耐药性的机制.
- 通过分析多组学数据来确定骨髓瘤的新型治疗点.
主要方法:
- 转录基因组学,蛋白质基因组学和光蛋白质基因组学在对待雷戈拉费尼布的骨髓瘤细胞系上进行.
- 进行了差异基因表达分析和功能测定 (体外和临床标本).
- 免疫组织化学被用来验证已识别的基因的上调.
主要成果:
- 综合的多组学分析确定CTDSPL2是一种可能参与骨髓瘤恶性病变和对regorafenib耐药性的基因.
- CTDSPL2促进骨髓瘤细胞的增殖,入侵和转移,同时抑制细胞亡.
- 抑制CTDSPL2显著降低了瘤细胞的生长,入侵和转移.
结论:
- CTDSPL2是骨髓瘤细胞存活和瘤发育的重要基因.
- CTDSPL2在骨髓瘤的进展和对regorafenib的耐药性方面发挥着重要作用.
- CTDSPL2代表了骨髓瘤治疗的潜在治疗标.
更多相关视频
06:00Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
Published on: September 13, 2017
11:13Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
相关概念视频
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Inhibition of Cdk Activity
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Abnormal Proliferation
Mitogens and the Cell Cycle
